Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by MidWestOne Financial Group Inc.

MidWestOne Financial Group Inc. grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,631 shares of the medical research company’s stock after acquiring an additional 23 shares during the period. MidWestOne Financial Group Inc.’s holdings in Thermo Fisher Scientific were worth $2,561,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of TMO. Kathmere Capital Management LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth approximately $375,000. Goodman Advisory Group LLC raised its holdings in Thermo Fisher Scientific by 40.9% during the second quarter. Goodman Advisory Group LLC now owns 465 shares of the medical research company’s stock worth $257,000 after purchasing an additional 135 shares in the last quarter. Sepio Capital LP raised its holdings in Thermo Fisher Scientific by 7.6% during the second quarter. Sepio Capital LP now owns 3,980 shares of the medical research company’s stock worth $2,201,000 after purchasing an additional 282 shares in the last quarter. Security National Bank of SO Dak raised its holdings in Thermo Fisher Scientific by 4.2% during the second quarter. Security National Bank of SO Dak now owns 8,698 shares of the medical research company’s stock worth $4,810,000 after purchasing an additional 349 shares in the last quarter. Finally, Scientech Research LLC raised its holdings in Thermo Fisher Scientific by 24.2% during the second quarter. Scientech Research LLC now owns 2,724 shares of the medical research company’s stock worth $1,506,000 after purchasing an additional 531 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Lisa P. Britt sold 3,624 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares in the company, valued at approximately $8,397,760.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. Insiders sold a total of 23,084 shares of company stock valued at $14,094,292 in the last quarter. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.8 %

Thermo Fisher Scientific stock opened at $614.42 on Friday. The company’s fifty day simple moving average is $606.08 and its 200-day simple moving average is $582.06. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $627.88. The stock has a market cap of $234.71 billion, a P/E ratio of 39.41, a P/E/G ratio of 3.88 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter in the previous year, the business earned $5.15 EPS. Thermo Fisher Scientific’s quarterly revenue was down 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Wall Street Analyst Weigh In

Several research firms have issued reports on TMO. Bank of America lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Royal Bank of Canada restated an “outperform” rating and issued a $767.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 20th. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Finally, Stifel Nicolaus lifted their price objective on shares of Thermo Fisher Scientific from $615.00 to $680.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $647.78.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.